MCID: CNT060
MIFTS: 44

Central Serous Chorioretinopathy

Categories: Rare diseases, Eye diseases, Bone diseases, Immune diseases

Aliases & Classifications for Central Serous Chorioretinopathy

MalaCards integrated aliases for Central Serous Chorioretinopathy:

Name: Central Serous Chorioretinopathy 53 59 73
Central Serous Chorioretinopathy After Bone Marrow Transplantation 53
Central Serous Choroidopathy 53
Cscr 59

Characteristics:

Orphanet epidemiological data:

59
central serous chorioretinopathy
Inheritance: Not applicable;

Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

Orphanet 59 ORPHA443079
ICD10 via Orphanet 34 H35.7
UMLS via Orphanet 74 C0730328
UMLS 73 C0730328

Summaries for Central Serous Chorioretinopathy

NIH Rare Diseases : 53 Central serous chorioretinopathy is a disease that causes fluid to build up under the retina, the back part of the inner eye that sends sight information to the brain. The fluid leaks from the choroid (the blood vessel layer under the retina). The cause of this condition is unknown but stress can be a risk factor. Signs and symptoms include dim and blurred blind spot in the center of vision, distortion of straight lines and seeing objects as smaller or farther away. Many cases of central serous chorioretinopathy improve without treatment after 1-2 months. Laser treatment may be an option for other individuals.

MalaCards based summary : Central Serous Chorioretinopathy, also known as central serous chorioretinopathy after bone marrow transplantation, is related to choroiditis and retinitis. An important gene associated with Central Serous Chorioretinopathy is CFH (Complement Factor H), and among its related pathways/superpathways are Complement Pathway and Senescence and Autophagy in Cancer. The drugs Spironolactone and Eplerenone have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone marrow, and related phenotypes are cardiovascular system and renal/urinary system

Related Diseases for Central Serous Chorioretinopathy

Diseases related to Central Serous Chorioretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 choroiditis 31.9 ARMS2 CFH
2 retinitis 10.8
3 retinal detachment 10.5
4 catastrophic antiphospholipid syndrome 10.4 CFH SERPINE1
5 multifocal choroiditis 10.4 ARMS2 CFH
6 retinal drusen 10.4 ARMS2 CFH
7 macular degeneration, age-related, 1 10.4
8 kuhnt-junius degeneration 10.4 ARMS2 CFH
9 aging 10.4
10 endotheliitis 10.3
11 degeneration of macula and posterior pole 10.3 ARMS2 CFH
12 apnea, obstructive sleep 10.2
13 sleep apnea 10.2
14 fibrinolytic defect 10.2 PLAT SERPINE1
15 plasminogen activator inhibitor-1 deficiency 10.2 PLAT SERPINE1
16 argentine hemorrhagic fever 10.2 PLAT SERPINE1
17 carotid artery thrombosis 10.1 PLAT SERPINE1
18 vogt-koyanagi-harada disease 10.1
19 acute cor pulmonale 10.1 PLAT SERPINE1
20 thrombophlebitis 10.1 PLAT SERPINE1
21 acute pulmonary heart disease 10.1 PLAT SERPINE1
22 coronary thrombosis 10.1 PLAT SERPINE1
23 chronic venous insufficiency 10.1 PLAT SERPINE1
24 hepatic veno-occlusive disease 10.1 PLAT SERPINE1
25 venous insufficiency 10.1 PLAT SERPINE1
26 systemic lupus erythematosus 10.0
27 retinitis pigmentosa 10.0
28 leber congenital amaurosis 4 10.0
29 ulcerative colitis 10.0
30 colitis 10.0
31 uveitis 10.0
32 impotence 10.0
33 optic nerve disease 10.0
34 adrenal gland hyperfunction 10.0
35 retinal degeneration 10.0
36 neuropathy 10.0
37 lupus erythematosus 10.0
38 chorioretinitis 10.0
39 psoriasis 10.0
40 thrombophilia due to activated protein c resistance 10.0 PLAT SERPINE1
41 retinal disease 10.0 ARMS2 CFH
42 thrombophilia due to thrombin defect 10.0 PLAT SERPINE1
43 disseminated intravascular coagulation 10.0 PLAT SERPINE1
44 pulmonary embolism 10.0 PLAT SERPINE1
45 hallermann-streiff syndrome 9.9
46 peripheral vascular disease 9.9 PLAT SERPINE1
47 gastroesophageal reflux 9.9
48 multiple sclerosis 9.9
49 macular dystrophy, dominant cystoid 9.9
50 pulmonary hypertension, primary, 1 9.9

Graphical network of the top 20 diseases related to Central Serous Chorioretinopathy:



Diseases related to Central Serous Chorioretinopathy

Symptoms & Phenotypes for Central Serous Chorioretinopathy

MGI Mouse Phenotypes related to Central Serous Chorioretinopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.35 C4B CFH NR3C2 PLAT SERPINE1
2 renal/urinary system MP:0005367 8.92 C4B CFH NR3C2 SERPINE1

Drugs & Therapeutics for Central Serous Chorioretinopathy

Drugs for Central Serous Chorioretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 4,Phase 2,Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
2
Eplerenone Approved Phase 4,Phase 2,Phase 3,Not Applicable 107724-20-9 150310 443872
3
Verteporfin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 129497-78-5
4
Ranibizumab Approved Phase 4,Phase 1,Phase 2 347396-82-1 459903
5 diuretics Phase 4,Phase 2,Phase 3,Not Applicable
6 Mineralocorticoid Receptor Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
7 Mineralocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
8 Natriuretic Agents Phase 4,Phase 2,Phase 3,Not Applicable
9 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Dermatologic Agents Phase 4,Phase 2,Phase 1,Not Applicable
11 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 3,Not Applicable
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Photosensitizing Agents Phase 4,Phase 1,Phase 2,Not Applicable
17
Bevacizumab Approved, Investigational Phase 2, Phase 3,Not Applicable 216974-75-3
18
Trametinib Approved Phase 3,Phase 2 871700-17-3 11707110
19
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760 44516822
20 Protein Kinase Inhibitors Phase 3,Phase 2
21
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
22
Zinc Approved, Investigational Phase 2 7440-66-6 23994
23
Gemcitabine Approved Phase 2 95058-81-4 60750
24
Copper Approved, Investigational Phase 2 7440-50-8 27099
25
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
26
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
27
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
28
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
29
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
30
Finasteride Approved Phase 1, Phase 2,Phase 2 98319-26-7 57363
31
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
32
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
33
Ketoconazole Approved, Investigational Phase 2 65277-42-1 47576 3823
34
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
36
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
37
Lutein Approved, Investigational, Nutraceutical Phase 2 127-40-2 6433159
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
39
Tocopherol Approved, Investigational, Nutraceutical Phase 2 1406-66-2 14986
40
Manganese Approved, Nutraceutical Phase 2 7439-96-5 27854
41
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
43
Lactitol Investigational Phase 1, Phase 2,Not Applicable 585-86-4 3871
44 Anecortave Investigational Phase 1, Phase 2 10184-70-0
45 Folic Acid Antagonists Phase 2
46 Nucleic Acid Synthesis Inhibitors Phase 2
47 Vitamin B Complex Phase 2
48 Immunosuppressive Agents Phase 2
49 Antirheumatic Agents Phase 2
50 Antimetabolites Phase 2

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Unknown status NCT02681783 Phase 4 aflibercept
2 Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy Completed NCT01797861 Phase 4
3 Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population Completed NCT02462499 Phase 4 Inspra (eplerenone)
4 Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Completed NCT01574430 Phase 4
5 Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Recruiting NCT03079141 Phase 4 Eplerenone
6 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
7 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
8 Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Unknown status NCT00418431 Phase 2, Phase 3 Intravitreal injection of Bevacizumab
9 Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy Recruiting NCT02735213 Phase 2, Phase 3
10 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Active, not recruiting NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
11 Methotrexate for Central Serous Chorioretinopathy Treatment Trial Unknown status NCT01633983 Phase 2 Methotrexate;Delayed treatment
12 Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT02153125 Phase 2 Eplerenone
13 Eplerenone for Central Serous Chorioretinopathy Completed NCT01822561 Phase 2 Eplerenone 50mg
14 Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Completed NCT02354170 Phase 2 Mifepristone;Placebo
15 High-dose Antioxidants for Central Serous Chorioretinopathy Completed NCT00963131 Phase 2 antioxidants tablets
16 Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Completed NCT00489840 Phase 1, Phase 2 Anecortave Acetate Sterile suspension 15 mg;Anecortave Acetate
17 Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Completed NCT00817245 Phase 1, Phase 2 omeprazole, Amoxicillin, metronidazole
18 The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Completed NCT01710332 Phase 2 Intravitreal Aflibercept Injection
19 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
20 Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01325181 Phase 1, Phase 2 Verteporfin;ranibizumab
21 A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Completed NCT00211393 Phase 2 ketoconazole
22 Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Completed NCT00987077 Phase 2
23 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
24 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT00837252 Phase 1, Phase 2 Finasteride
25 Topical Interferon Gamma-1b for Central Serous Chorioretinopathy Completed NCT01468337 Phase 1, Phase 2 Interferon gamma-1b
26 Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Completed NCT00211445 Phase 2 verteporfin
27 Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer Completed NCT01231581 Phase 2 GSK1120212;Gemcitabine;Placebo
28 Endpoint Management Software for Photothermal Stimulation of Macular Diseases Recruiting NCT01975103 Phase 2
29 Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy Not yet recruiting NCT03542006 Phase 2 Brinzolamide Ophthalmic
30 Finasteride for Chronic Central Serous Chorioretinopathy Terminated NCT01585441 Phase 2 Finasteride;Placebo
31 Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Completed NCT00403325 Phase 1 rhuFab V2 [ranibizumab] ( Lucentis )
32 Eye Patch Therapy for Central Serous Retinopathy (CSR) Completed NCT02036632 Phase 1
33 The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Unknown status NCT01630863 Not Applicable
34 The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Unknown status NCT00864773 Not Applicable
35 Pseudo-PDT in Central Serous Chorioretinopathy Unknown status NCT02799992 Not Applicable
36 Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers Unknown status NCT02815176
37 Selective RPE Laser Treatment (SRT) for Various Macular Diseases Unknown status NCT00403884 Not Applicable
38 Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Completed NCT01019668 Not Applicable Verteporfin PDT, half-dose;verteporfin PDT, half-fluence
39 Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Completed NCT01327170 Not Applicable
40 Central Serous Chorioretinopathy: Etiology, Course and Prognosis Completed NCT01378130
41 Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Completed NCT00803517
42 Eplerenone for the Treatment of Central Serous Chorioretinopathy Completed NCT01990677 Not Applicable 25mg Eplerenone;Placebo
43 Persona of Central Serous Chorioretinopathy Completed NCT02819622
44 Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Completed NCT03339856 Not Applicable
45 Effects of OCTA-guided PDT in Acute CSC Completed NCT03497000 Not Applicable
46 Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Completed NCT00802906 Not Applicable bevacizumab
47 Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Completed NCT01434095 Not Applicable
48 Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Completed NCT01880788
49 Choroidal Thickness Measurements During Central Serous Chorioretinopathy (CSCR) Treatment Completed NCT01610804
50 Evaluation and Treatment of Patients With Retinal Disease Completed NCT00005784

Search NIH Clinical Center for Central Serous Chorioretinopathy

Genetic Tests for Central Serous Chorioretinopathy

Anatomical Context for Central Serous Chorioretinopathy

MalaCards organs/tissues related to Central Serous Chorioretinopathy:

41
Eye, Retina, Bone Marrow, Bone, Brain, Endothelial, Testes

Publications for Central Serous Chorioretinopathy

Articles related to Central Serous Chorioretinopathy:

(show top 50) (show all 691)
# Title Authors Year
1
Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group. ( 29439089 )
2018
2
Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. ( 29922035 )
2018
3
Leopard-Spot Subretinal Deposits in Central Serous Chorioretinopathy. ( 29697592 )
2018
4
The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. ( 29671064 )
2018
5
Central Serous Chorioretinopathy Associated with Desmopressin Nasal Spray: Causality or Unfortunate Association. ( 29643793 )
2018
6
Mineralocorticoid receptor inhibitor for long-standing central serous chorioretinopathy. ( 29671951 )
2018
7
Central serous chorioretinopathy following medial transposition of split lateral rectus muscle for complete oculomotor nerve palsy. ( 29331454 )
2018
8
Clinical Features of Central Serous Chorioretinopathy with Type 1 Choroidal Neovascularization. ( 29940168 )
2018
9
Macular Integrity Assessment and Fixation Analysis in Chronic Central Serous Chorioretinopathy. ( 29725542 )
2018
10
Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy. ( 29876733 )
2018
11
CORRELATIONS BETWEEN CHANGES IN PHOTORECEPTOR LAYER AND OTHER CLINICAL CHARACTERISTICS IN CENTRAL SEROUS CHORIORETINOPATHY. ( 29401176 )
2018
12
Proteome and Metabolome of Subretinal Fluid in Central Serous Chorioretinopathy and Rhegmatogenous Retinal Detachment: A Pilot Case Study. ( 29359109 )
2018
13
<i>CFH</i> and <i>VIPR2</i> as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy. ( 29844195 )
2018
14
Sub-internal Limiting Membrane Cavity Following Valsalva Retinopathy Resembling Central Serous Chorioretinopathy. ( 29403598 )
2018
15
Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. ( 29303148 )
2018
16
Findings of OCT-angiography compared to fluorescein and indocyanine green angiography in central serous chorioretinopathy. ( 29896889 )
2018
17
Central serous chorioretinopathy with angioid streaks: a rare combination. ( 29623251 )
2018
18
Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. ( 29303152 )
2018
19
Topography-guided identification of leakage point in central serous chorioretinopathy: a base for fluorescein angiography-free focal laser photocoagulation. ( 29301768 )
2018
20
Torpedo maculopathy with multifocal central serous chorioretinopathy: A rare case report. ( 29380797 )
2018
21
Central Serous Chorioretinopathy in African Americans at Wilmer Eye Institute. ( 29778134 )
2018
22
Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy. ( 29916122 )
2018
23
Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy. ( 29429986 )
2018
24
SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY. ( 29595560 )
2018
25
Eplerenone Versus Observation in the Treatment of Acute Central Serous Chorioretinopathy: A Retrospective Controlled Study. ( 29442283 )
2018
26
Retinal and choroidal changes in steroid-associated central serous chorioretinopathy. ( 29619248 )
2018
27
CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. ( 29346241 )
2018
28
Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. ( 29732468 )
2018
29
A potential side effect of oral topical steroids: Central serous chorioretinopathy. ( 29442094 )
2018
30
Early Choriocapillaris Changes After Half-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy Evaluated by Optical Coherence Tomography Angiography: Preliminary Results. ( 29409857 )
2018
31
Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. ( 29776672 )
2018
32
Correlation between morphological characteristics in spectral-domain-optical coherence tomography, different functional tests and a patient's subjective handicap in acute central serous chorioretinopathy. ( 29338130 )
2018
33
CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY. ( 29016451 )
2018
34
Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy. ( 29424884 )
2018
35
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERISTICS OF POLYPOIDAL CHOROIDAL VASCULOPATHY SECONDARY TO CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. ( 29965937 )
2018
36
Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathy. ( 29656602 )
2018
37
Central serous chorioretinopathy: Current update on pathophysiology and multimodal imaging. ( 29930442 )
2018
38
Central Serous Chorioretinopathy in a Patient with Ulcerative Colitis with Pouchitis on Budesonide-EC. ( 28328626 )
2017
39
Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy. ( 28798899 )
2017
40
Relationship between choroidal blood flow velocity and choroidal thickness in patients with regression of acute central serous chorioretinopathy. ( 28889224 )
2017
41
Photoreceptor assessment using adaptive optics in resolved central serous chorioretinopathy. ( 28832731 )
2017
42
Acute lupus choroidopathy: multimodal imaging and differential diagnosis from central serous chorioretinopathy. ( 28050729 )
2017
43
Central serous chorioretinopathy mimicking as choroiditis. ( 29134698 )
2017
44
Pattern of Contrast Sensitivity Changes in Acute Central Serous Chorioretinopathy. ( 29423320 )
2017
45
Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy. ( 28334414 )
2017
46
CYSTOID MACULAR EDEMA AND CYSTOID MACULAR DEGENERATION AS A RESULT OF MULTIPLE PATHOGENIC FACTORS IN THE SETTING OF CENTRAL SEROUS CHORIORETINOPATHY. ( 27902539 )
2017
47
Multimodal assessment of patients with chronic central serous chorioretinopathy. ( 28832738 )
2017
48
Visual and Anatomical Outcomes of Spironolactone Therapy in Patients with Chronic Central Serous Chorioretinopathy. ( 28791061 )
2017
49
Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy. ( 28797227 )
2017
50
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. ( 28709702 )
2017

Variations for Central Serous Chorioretinopathy

Expression for Central Serous Chorioretinopathy

Search GEO for disease gene expression data for Central Serous Chorioretinopathy.

Pathways for Central Serous Chorioretinopathy

GO Terms for Central Serous Chorioretinopathy

Biological processes related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of complement activation GO:0030449 9.16 C4B CFH
2 complement activation GO:0006956 8.96 C4B CFH
3 fibrinolysis GO:0042730 8.62 PLAT SERPINE1

Sources for Central Serous Chorioretinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....